Page 5 - Inborn Errors News Today

Sangamo Therapeutics, Inc. (NASDAQ:NASDAQ:SGMO) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief...

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced its intention to file a Biologics License Application (BLA) in 2024 using the FDAs accelerated...

The fact that metabolomics has the ability to detect a large number of metabolites from fluid or tissue samples in a single step and it can also yield great amounts leads to a steep rise in

/PRNewswire/ -- Allied Market Research published a report, titled, "Metabolomics Market by Product and Service (Metabolomics Instruments and Metabolomics...

Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C - read this article along with other careers information, tips and advice on BioSpace

24.01.2022 - REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) - Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the ... Seite 1

POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis

/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced...

PPS was well tolerated with no serious adverse events reported over a 24-week period and there were meaningful improvements in pain, function...

/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced...